Kura Oncology (NASDAQ:KURA) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Kura Oncology (NASDAQ:KURA) posted its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03), Briefing.com reports. Kura Oncology’s revenue was up .0% on a year-over-year basis. During the same period last year, the company posted ($0.50) EPS.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $20.63 on Friday. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17. The company’s fifty day moving average price is $20.66 and its 200-day moving average price is $15.94. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 0.02.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Wedbush reissued an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a report on Friday. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. JMP Securities upped their target price on shares of Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a research report on Wednesday, January 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a report on Friday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.28.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.